本文選題：胃腸道間質(zhì)瘤 + 復(fù)發(fā)轉(zhuǎn)移　； 參考：《胃腸病學(xué)和肝病學(xué)雜志》2017年03期

【摘要】：目的探討胃腸道間質(zhì)瘤(gastrointestinal stromal tumor,GIST)復(fù)發(fā)轉(zhuǎn)移危險因素。方法回顧性分析108例經(jīng)手術(shù)證實的GIST患者的臨床資料,并分析影響其復(fù)發(fā)轉(zhuǎn)移的危險因素。結(jié)果 108例患者4年累計復(fù)發(fā)轉(zhuǎn)移率為29.63%,單因素分析顯示腫瘤大小、核分裂象數(shù)、腫瘤原發(fā)部位、術(shù)后服用伊馬替尼、Ki67指數(shù)與GIST復(fù)發(fā)轉(zhuǎn)移有關(guān)(P0.05),多因素分析顯示腫瘤大小、核分裂象數(shù)、腫瘤原發(fā)部位、術(shù)后服用伊馬替尼是影響GIST復(fù)發(fā)轉(zhuǎn)移的獨立危險因素。結(jié)論腫瘤大小、核分裂象、腫瘤原發(fā)部位是GIST復(fù)發(fā)轉(zhuǎn)移的獨立危險因素,術(shù)后伊馬替尼分子靶向治療可明顯降低GIST復(fù)發(fā)轉(zhuǎn)移風(fēng)險。
[Abstract]:Objective to investigate the risk factors of recurrence and metastasis of gastrointestinal stromal tumors (GIST). Methods the clinical data of 108 patients with GIST confirmed by operation were retrospectively analyzed and the risk factors affecting their recurrence and metastasis were analyzed. Results the cumulative recurrence and metastasis rate of 108 patients in 4 years was 29.63. Single factor analysis showed that tumor size, mitotic number, primary location of the tumor, postoperative use of imatinib Ki67 index and GIST recurrence and metastasis were related to P0.05, multivariate analysis showed tumor size. Mitotic number, primary site of tumor, postoperative administration of imatinib were independent risk factors for recurrence and metastasis of GIST. Conclusion tumor size, mitotic image and primary tumor site are independent risk factors for recurrence and metastasis of GIST. Imatinib molecular targeted therapy after operation can significantly reduce the risk of recurrence and metastasis of GIST.
【作者單位】： 重慶醫(yī)科大學(xué)附屬第一醫(yī)院消化內(nèi)科;
【分類號】：R735

【參考文獻(xiàn)】

相關(guān)期刊論文 前8條

1 曹暉;汪明;;NCCN《軟組織肉瘤——胃腸間質(zhì)瘤臨床實踐指南(2015年第1版)》更新介紹與解讀[J];中國實用外科雜志;2015年06期

2 楊健;于健春;馬志強;康維明;田樹波;葉欣;;胃腸道間質(zhì)瘤558例臨床病理特征及預(yù)后分析[J];中華外科雜志;2015年04期

3 周雪;陳瑤;吳s，

本文編號：1845887